免疫性血小板减少症的最佳二线治疗方法是什么？

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2024-10-16 DOI:10.1111/bjh.19777

Matthieu Mahévas, James B. Bussel

{"title":"免疫性血小板减少症的最佳二线治疗方法是什么？","authors":"Matthieu Mahévas, James B. Bussel","doi":"10.1111/bjh.19777","DOIUrl":null,"url":null,"abstract":"The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain weaknesses. Stolz et al. describe a single-centre experience that whets our appetite for a large randomized controlled trial comparing a TPO agonist and an anti-CD20 agent.Commentary on: Stolz et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia – A single center retrospective analysis. Br J Haematol 2024; 205:1121-1125.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 4","pages":"1267-1268"},"PeriodicalIF":5.1000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19777","citationCount":"0","resultStr":"{\"title\":\"What is the best second-line treatment for immune thrombocytopenia?\",\"authors\":\"Matthieu Mahévas, James B. Bussel\",\"doi\":\"10.1111/bjh.19777\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain weaknesses. Stolz et al. describe a single-centre experience that whets our appetite for a large randomized controlled trial comparing a TPO agonist and an anti-CD20 agent.Commentary on: Stolz et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia – A single center retrospective analysis. Br J Haematol 2024; 205:1121-1125.\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\"205 4\",\"pages\":\"1267-1268\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19777\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19777\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19777","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

作为治疗免疫性血小板减少症的二线疗法，促血小板生成素受体激动剂（TPO-RA）和抗 CD20 之间的选择仍是众说纷纭。每种疗法都有其主要优势和某些弱点。Stolz等人描述了一个单中心的经验，让我们对比较TPO激动剂和抗CD20药物的大型随机对照试验产生了兴趣：Stolz et al.Br J Haematol 2024; 205:1121-1125.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

What is the best second-line treatment for immune thrombocytopenia?

The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain weaknesses. Stolz et al. describe a single-centre experience that whets our appetite for a large randomized controlled trial comparing a TPO agonist and an anti-CD20 agent.

Commentary on: Stolz et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia – A single center retrospective analysis. Br J Haematol 2024; 205:1121-1125.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.